시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 세균성 결막염 시장 보고서(2025년)
Bacterial Conjunctivitis Global Market Report 2025
상품코드 : 1681920
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,181,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,934,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,688,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세균성 결막염 시장 규모는 향후 몇 년 동안 안정적인 성장세를 보일 것으로 예상되며, 2029년까지 3.8%의 연평균 복합 성장률(CAGR)로 55억 4,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 세계 인구 증가, 도시화 및 오염 증가, 예방 안과 의료에 대한 관심 증가, 세계 건강 준비 노력, 원격 안과 서비스 확대, 연구 개발 협력에 기인합니다. 예측 기간의 주요 동향으로는 약물 전달 기술의 혁신, 치료 요법의 맞춤화, 광범위 항생제 사용, 보조 요법의 도입, 환자 교육 및 예방 전략의 중요성 등이 있습니다.

세균성 결막염 시장은 안구 감염증의 유병률 증가로 인해 성장할 것으로 예상됩니다. 세균, 바이러스, 곰팡이, 기생충과 같은 미생물에 의해 발생하는 안구 감염에는 결막염, 트라코마, 각막염과 같은 질환이 포함됩니다. 세균성 결막염, 처방된 약물과 위생 조치로 치료할 수 있는 특정 유형의 결막염은 증가하는 추세입니다. 예를 들어, 2021년 세계보건기구(WHO)는 약 69,000명이 눈의 세균 감염인 트라코마 말기 단계에서 수술을 받았고, 6,460만 명이 트라코마에 대한 항생제 치료를 받았다고 보고했습니다. 또한, 브라이트포커스 재단은 전 세계 녹내장 환자가 2022년 8,000만 명에 달하고, 2040년에는 1억 1,100만 명에 육박할 것으로 예측했습니다. 따라서 안구 감염증의 유병률 증가가 세균성 결막염 시장 성장의 원동력이 되고 있습니다.

세균성 결막염 시장은 노인 인구 증가로 인해 성장이 촉진될 것으로 예상되며, 65세 이상 노인은 노화에 따른 면역 체계의 변화와 동반 질환의 가능성이 높아 세균성 결막염에 더 취약하며, 2022년 10월 세계보건기구(WHO) 보고서에 따르면 2030년까지 전 세계 인구 6명 중 1명이 60세 이상이 될 것으로 예상됩니다. 6명 중 1명이 60세 이상이 되어 14억 명에 달할 것으로 예측됩니다. 또한 2050년에는 60세 이상 인구가 2배인 21억 명, 80세 이상 인구는 3배인 4억2600만 명에 달할 것으로 예측됩니다. 이러한 고령화 사회로의 인구통계학적 변화는 세균성 결막염 시장을 견인하는 중요한 요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

LSH
영문 목차

영문목차

Bacterial conjunctivitis is an infection affecting the mucous membrane of the eye, known as the conjunctiva. This membrane extends from the back surface of the eyelids (palpebral and tarsal conjunctiva) to the fornices and over the globe (bulbar conjunctiva) until it merges with the cornea at the limbus. This condition is highly contagious, easily transmitted through direct or indirect contact with the infected person's eye secretions.

The primary types of bacterial conjunctivitis include hyperacute bacterial conjunctivitis, acute bacterial conjunctivitis, and chronic bacterial conjunctivitis. Hyperacute bacterial conjunctivitis is an exceptionally severe and rapidly progressing form of this infection, characterized by inflammation of the conjunctiva. Various drug classes, such as antibiotics, fluoroquinolones, aminoglycosides, macrolides, antihistamines, corticosteroids, and others, are available for treatment. These medications can be administered through different routes, including oral and topical. Distribution channels for these drugs encompass hospital pharmacies, retail pharmacies, online pharmacies, and other outlets.

The bacterial conjunctivitis market research report is one of a series of new reports from The Business Research Company that provides bacterial conjunctivitis market statistics, including bacterial conjunctivitis industry global market size, regional shares, competitors with a bacterial conjunctivitis market share, detailed bacterial conjunctivitis market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial conjunctivitis industry. This bacterial conjunctivitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bacterial conjunctivitis market size has grown strongly in recent years. It will grow from $4.52 billion in 2024 to $4.76 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing incidence of bacterial infections, improved diagnostic capabilities, patient education and awareness programs, stringent regulatory framework, physician training and expertise.

The bacterial conjunctivitis market size is expected to see steady growth in the next few years. It will grow to $5.54 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to global population growth, rising urbanization and pollution, increased focus on preventive eye care, global health preparedness initiatives, expansion of teleophthalmology services, collaboration in research and development. Major trends in the forecast period include innovation in drug delivery technologies, customization of treatment regimens, utilization of broad-spectrum antibiotics, introduction of adjunctive therapies, emphasis on patient education and prevention strategies.

The bacterial conjunctivitis market is poised for growth due to the increasing prevalence of eye infections. Eye infections, caused by microorganisms such as bacteria, viruses, fungi, or parasites, encompass conditions such as conjunctivitis, trachoma, and keratitis. Bacterial conjunctivitis, a specific type treatable with prescribed medications and hygiene measures, is on the rise. For instance, in 2021, the World Health Organization reported that approximately 69,000 people underwent surgery for the late stage of trachoma, an eye bacterial infection, while 64.6 million received antibiotics treatment for trachoma. Additionally, The BrightFocus Foundation noted that the global glaucoma sufferers reached 80 million in 2022, projected to rise to nearly 111 million by 2040. Hence, the increasing prevalence of eye infections is a driving force behind the growth of the bacterial conjunctivitis market.

The bacterial conjunctivitis market is expected to experience growth fueled by the increasing geriatric population. Individuals aged 65 and older are more susceptible to bacterial conjunctivitis due to age-related changes in the immune system and a higher likelihood of comorbidities. The World Health Organization's report in October 2022 projected that by 2030, 1 in 6 people globally would be aged 60 or above, reaching 1.4 billion. Furthermore, by 2050, the population aged 60 and older is expected to double to 2.1 billion, with those 80 and older tripling to 426 million. This demographic shift toward an aging population is a key factor driving the bacterial conjunctivitis market.

Major players in the bacterial conjunctivitis market are intensifying their efforts to develop innovative eye drops, particularly broad-spectrum eye drops, to optimize their revenues. These medications are specifically formulated to address various eye infections caused by diverse bacteria. Unsuch as targeting specific bacterial types, broad-spectrum eye drops contain antibiotics effective against a wide range of bacteria. An example of this is the launch of Vigamox (moxifloxacin hydrochloride ophthalmic solution) 0.5% by Harrow Health, a US-based pharmaceutical company, in June 2023. Vigamox, a fluoroquinolone antibiotic eye drop, is designed for the treatment of bacterial conjunctivitis.

In January 2023, Harrow Health further strengthened its position in the ophthalmic pharmaceutical market by acquiring the U.S. commercial rights to five ophthalmic drugs, namely Ilevro, Nevanac, Vigamox, Maxidex, and Triesence, from Novartis AG for $175 million. This strategic acquisition is expected to support Harrow Health's expansion in the field of ophthalmology, serving as a valuable addition to its geographic reach. Novartis AG, a Swiss-based pharmaceutical company, specializes in offering a diverse range of medications tailored to treat various eye conditions, including bacterial conjunctivitis.

Major companies operating in the bacterial conjunctivitis market report are Pfizer Inc., Johnson & Johnson, F. Hoffman La-Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Alcon, Sun Pharmaceutical Industries Ltd., Bausch + Lomb, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Hikma Pharmaceuticals, Santen Pharmaceutical Co. Ltd., Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Alembic Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Ocular Therapeutix Inc., Aldeyra Therapeutics, Nicox SA, IACTA Pharmaceuticals Inc., Cellics Therapeutics Inc.

North America was the largest region in the bacterial conjunctivitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bacterial conjunctivitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bacterial conjunctivitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bacterial conjunctivitis market consists of revenues earned by entities by providing services such as diagnostic tests, visual acuity testing, and physical examinations. The market value includes the value of related goods sold by the service provider or included within the service offering. The bacterial conjunctivitis market also includes sales of eye drops, eye ointments, cold compresses, and artificial tears. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bacterial Conjunctivitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bacterial conjunctivitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for bacterial conjunctivitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bacterial conjunctivitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Bacterial Conjunctivitis Market Characteristics

3. Bacterial Conjunctivitis Market Trends And Strategies

4. Bacterial Conjunctivitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Bacterial Conjunctivitis Growth Analysis And Strategic Analysis Framework

6. Bacterial Conjunctivitis Market Segmentation

7. Bacterial Conjunctivitis Market Regional And Country Analysis

8. Asia-Pacific Bacterial Conjunctivitis Market

9. China Bacterial Conjunctivitis Market

10. India Bacterial Conjunctivitis Market

11. Japan Bacterial Conjunctivitis Market

12. Australia Bacterial Conjunctivitis Market

13. Indonesia Bacterial Conjunctivitis Market

14. South Korea Bacterial Conjunctivitis Market

15. Western Europe Bacterial Conjunctivitis Market

16. UK Bacterial Conjunctivitis Market

17. Germany Bacterial Conjunctivitis Market

18. France Bacterial Conjunctivitis Market

19. Italy Bacterial Conjunctivitis Market

20. Spain Bacterial Conjunctivitis Market

21. Eastern Europe Bacterial Conjunctivitis Market

22. Russia Bacterial Conjunctivitis Market

23. North America Bacterial Conjunctivitis Market

24. USA Bacterial Conjunctivitis Market

25. Canada Bacterial Conjunctivitis Market

26. South America Bacterial Conjunctivitis Market

27. Brazil Bacterial Conjunctivitis Market

28. Middle East Bacterial Conjunctivitis Market

29. Africa Bacterial Conjunctivitis Market

30. Bacterial Conjunctivitis Market Competitive Landscape And Company Profiles

31. Bacterial Conjunctivitis Market Other Major And Innovative Companies

32. Global Bacterial Conjunctivitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bacterial Conjunctivitis Market

34. Recent Developments In The Bacterial Conjunctivitis Market

35. Bacterial Conjunctivitis Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기